arrow
P

Paschalis Vergidis

Mayo Clinic
H指数:32
被引数:2,921

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR

CD19嵌合抗原受体T细胞疗法治疗大B细胞淋巴瘤后的感染:CIBMTR的真实世界分析

2025-05-300
OAAI
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management

嵌合抗原受体T细胞治疗相关的噬血细胞性淋巴组织细胞增生症综合征: 临床表现、结果和管理

2024-08-120
OAAI
Reply to Kidd et al., Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion

对Kidd等人的答复,“稳定真菌命名风险的拟议框架内的不一致” 进一步混淆

2024-04-100
OA
Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy

接受嵌合抗原受体T细胞治疗的淋巴瘤患者免疫前抗体滴度的系列评估

2024-04-012
OAAI
A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC
2023-11-2128
OAAI
Description of Cryptococcosis Following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Disease Survey Through the Mycosis Study Group Education and Research Consortium (MSG-19)
2023-09-158
OAAI